Upcoming drug targets for kidney protective effects in chronic kidney disease
Overview
Paper Summary
This review highlights several new drug targets for chronic kidney disease (CKD) that show promise in slowing disease progression, particularly in patients with type 2 diabetes. These include glucagon-like peptide-1 receptor agonists (GLP1RA), aldosterone synthase inhibitors (ASI), endothelin receptor antagonists (ERA), and soluble guanylate cyclase (SGC) activators. Further research is needed to fully understand the mechanisms of action and optimize their clinical use.
Explain Like I'm Five
New medications show promise in protecting kidney function for people with chronic kidney disease, especially those with type 2 diabetes. More research is needed to figure out exactly how these drugs work and how best to use them.
Possible Conflicts of Interest
The review discloses funding from Bayer AG for the supplement in which it was published. Additionally, Dr. D. Z. I. Cherney, one of the authors, reports having received consulting fees, speaking honoraria, and operating funds from multiple pharmaceutical companies related to the therapies discussed in the review, including AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim-Lilly, Bristol-Myers Squibb, Janssen, JNJ, MAZE, Merck & Co., Inc., Mitsubishi-Tanabe, Novo Nordisk, Otsuka, Prometic, and Sanofi. He has also served as a scientific advisor for several of these companies.
Identified Limitations
Rating Explanation
This review summarizes promising new treatments for chronic kidney disease supported by clinical trial data. While some of the drugs discussed are already in use for related conditions like type 2 diabetes, their potential in specifically addressing CKD progression is a noteworthy advancement. The disclosed industry funding and potential conflicts of interest, though acknowledged, slightly lower the overall rating.
Good to know
This is the Starter analysis. Paperzilla Pro fact-checks every citation, researches author backgrounds and funding sources, and uses advanced AI reasoning for more thorough insights.
Explore Pro →